General information

Announcements(0)

Overview

Manual for Online Meeting

Participant Registration

Abstract Submission (Oral/Poster Presentation)

General information 2

Abstract Submission (Late-Breaking Session)

Program

Sessions

Search presentations

pharm141_en.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts. If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts. We will reply after confirming that you were a participant. Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Efficacy of in vitro rifampicin combination therapy against biofilm-producing S. aureus

Antimicrobial-resistant bacteria are the cause of death in an estimated 700,000 people annually worldwide, and this number is predicted to increase to 10 million by 2050 if efforts are not made to reduce resistance or develop new antibiotics. Therefore, research, development, and proper use of antibiotics are urgent issues. However, development is decreasing, and misuse and abuse remain common, which lead to their spread. In this symposium, 6 young pharmaceutical scientists will present from varying backgrounds of infectious research (pre-clinical studies [PCS] ~ clinical studies [CS]). Young scientists who are actively trying to overcome the threat and improve clinical antibacterial chemotherapy will share novel medical seeds found in daily research and their opinions. These seeds are expected to advance both PCS and CS, which will aid in the development of new therapies. After this symposium, young scientists who are performing PCS and CS are anticipated to collaborate organically with each other to develop innovative next-generation treatments. We consider this symposium to be a shortcut to overcoming antimicrobial-resistant bacteria.

Young pharmaceutical scientists accelerate translational research in infectious disease

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

Presentation Information

[GS01-2]Efficacy of in vitro rifampicin combination therapy against biofilm-producing S. aureus

Password required to view